Investment Thesis
Passage BIO is a pre-revenue biotech company with no commercial products and significant annual cash burn of $13M. While the balance sheet is unlevered with $33.3M in cash providing approximately 2.5 years of operational runway, the company faces fundamental challenges including negative ROE (-64.3%), negative ROA (-20.7%), and persistent operating losses. Without visibility into clinical development progress or near-term revenue catalysts, the financial fundamentals reveal a high-risk entity likely requiring additional capital raises and equity dilution before achieving profitability.
Strengths
- Zero debt with strong balance sheet structure enabling focus on R&D
- Adequate liquidity position with $33.3M cash and 1.73x current ratio providing near-term operational stability
- Low capital intensity with minimal capex requirements reducing cash burn drag
Risks
- Pre-revenue company with no demonstrated commercial viability or revenue-generating assets
- Annual cash burn of $13M against total assets of $36.5M creates limited financial runway of approximately 2.5 years without additional funding
- Shareholder value destruction evident in -64.3% ROE and -20.7% ROA with no visibility to profitability inflection
- Imminent need for capital raise will likely result in significant dilution to existing shareholders
Key Metrics to Watch
- Quarterly cash burn rate trend and runway extension
- Clinical trial advancement stage and regulatory milestones
- Capital raise announcements and terms (dilution percentage)
Financial Metrics
Revenue
N/A
Net Income
-7.6M
EPS (Diluted)
$-2.36
Free Cash Flow
-13.0M
Total Assets
36.5M
Cash
33.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-64.3%
ROA
-20.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.73x
Quick Ratio
1.73x
Debt/Equity
0.00x
Debt/Assets
67.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:58:50.490133 |
Data as of: 2026-03-31 |
Powered by Claude AI